{"id":"NCT02184195","sponsor":"AstraZeneca","briefTitle":"Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy","officialTitle":"A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12-16","primaryCompletion":"2019-01-15","completion":"2023-01-27","firstPosted":"2014-07-09","resultsPosted":"2020-01-27","lastUpdate":"2023-09-13"},"enrollment":154,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Germline BRCA1/2 Mutations and","Metastatic Adenocarcinoma of the Pancreas"],"interventions":[{"type":"DRUG","name":"Olaparib","otherNames":[]},{"type":"DRUG","name":"Olaparib","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Olaparib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy","primaryOutcome":{"measure":"Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1)","timeFrame":"Up to 4 years","effectByArm":[{"arm":"Olaparib 300 mg Twice Daily (bd)","deltaMin":7.4,"sd":null},{"arm":"Placebo","deltaMin":3.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0038"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":103,"countries":["United States","Australia","Belgium","Canada","France","Germany","Israel","Italy","Netherlands","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["31157963","35834777","35596182","33959007","33364840","32073954","31562758","29223478"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D081FC00001&amp;attachmentIdentifier=9095e288-3d26-4c56-87dd-5dedc61f25c2&amp;fileName=POLO_Revised_CSP_2-24Jul2019_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D081FC00001&amp;attachmentIdentifier=42f897a4-b682-4a0f-b2b0-cecf3f143423&amp;fileName=D081FC00001_Redacted_SAP.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D081FC00001&amp;attachmentIdentifier=adf11419-4145-42dc-bd0c-e36699d77c73&amp;fileName=D081FC00001_CSR_SynopsisRedacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":90},"commonTop":["Nausea","Fatigue","Diarrhoea","Abdominal pain","Back pain"]}}